Literature DB >> 11704689

Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study.

G Watt1, P Kantipong, K Jongsakul, M de Souza, T Burnouf.   

Abstract

We examined the HIV-inhibitory effects previously found to be associated with scrub typhus infection. Individual 500 ml units of plasma from donors with mild scrub typhus were safety-tested, subjected to virucidal heat treatment, and administered to 10 HIV-1-infected recipients who were not receiving antiretroviral drugs. HIV-1 copy number fell three-fold or more in two recipients, and virus burden was reduced for 8 weeks in 70% (7/10) of recipients of a single plasma infusion, compared with the mean of three pre-infusion measurements. Scrub typhus donor plasma inhibited HIV-1 in vitro compared with normal human plasma and media controls. In the clearest in vivo response, reduction in viral load was accompanied by clinical improvement, a switchback from the syncytia-inducing to the non-syncytia-inducing phenotype, and decreases in CD8 cells and IL-6 levels. Scrub typhus infections can generate heat-stable, transferable plasma factors that exert prolonged anti-HIV effects. Whether variability in the results is due to different scrub typhus infections, different HIV infections or different individual responses, is unclear.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704689     DOI: 10.1093/qjmed/94.11.599

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  10 in total

1.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

2.  Baboon CD8 T cells suppress SIVmac infection in CD4 T cells through contact-dependent production of MIP-1α, MIP-1β, and RANTES.

Authors:  Veronica Obregon-Perko; Vida L Hodara; Laura M Parodi; Luis D Giavedoni
Journal:  Cytokine       Date:  2018-05-26       Impact factor: 3.861

3.  Equine Immunoglobulin and Equine Neutralizing F(ab')₂ Protect Mice from West Nile Virus Infection.

Authors:  Jiannan Cui; Yongkun Zhao; Hualei Wang; Boning Qiu; Zengguo Cao; Qian Li; Yanbo Zhang; Feihu Yan; Hongli Jin; Tiecheng Wang; Weiyang Sun; Na Feng; Yuwei Gao; Jing Sun; Yanqun Wang; Stanley Perlman; Jincun Zhao; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2016-12-18       Impact factor: 5.048

Review 4.  Ebola virus convalescent blood products: where we are now and where we may need to go.

Authors:  Thierry Burnouf; Jerard Seghatchian
Journal:  Transfus Apher Sci       Date:  2014-10       Impact factor: 1.764

5.  Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice.

Authors:  Lili Zhou; Bing Ni; Deyan Luo; Guangyu Zhao; Zhengcai Jia; Liangyan Zhang; Zhihua Lin; Li Wang; Songle Zhang; Li Xing; Jintao Li; Yunfei Liang; Xinfu Shi; Tingting Zhao; Liyun Zhou; Yuzhang Wu; Xiliang Wang
Journal:  Int Immunopharmacol       Date:  2006-11-27       Impact factor: 4.932

6.  Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.

Authors:  Jiahai Lu; Zhongmin Guo; Xinghua Pan; Guoling Wang; Dingmei Zhang; Yanbin Li; Bingyan Tan; Liping Ouyang; Xinbing Yu
Journal:  Respir Res       Date:  2006-03-23

Review 7.  Natural Scrub Typhus Antibody Suppresses HIV CXCR4(X4) Viruses.

Authors:  George Watt; Pacharee Kantipong; Thierry Burnouf; Cecilia Shikuma; Sean Philpott
Journal:  Infect Dis Rep       Date:  2013-05-15

Review 8.  Convalescent Plasma Therapy for COVID-19: State of the Art.

Authors:  Daniele Focosi; Arthur O Anderson; Julian W Tang; Marco Tuccori
Journal:  Clin Microbiol Rev       Date:  2020-08-12       Impact factor: 26.132

9.  Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F(ab')2.

Authors:  Zhongpeng Zhao; Chuanbo Fan; Yueqiang Duan; Liangyan Zhang; Min Li; Xiaolan Yang; Ruisheng Li; Penghui Yang; Xiliang Wang
Journal:  Int Immunopharmacol       Date:  2014-09-02       Impact factor: 4.932

10.  Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.

Authors:  Yunsheng Xu; Zhengcai Jia; Liyun Zhou; Li Wang; Jintao Li; Yunfei Liang; Tingting Zhao; Bing Ni; Yuzhang Wu
Journal:  Int Immunopharmacol       Date:  2007-10-04       Impact factor: 4.932

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.